Hims & Hers Shares Plunge on Partnership Collapse and Legal Action

Hims & Hers Health, Inc. finds itself navigating a severe crisis as its stock faces substantial downward pressure. The telehealth company is reeling from a dual setback involving the abrupt termination of a crucial pharmaceutical partnership and the emergence of a significant class action lawsuit. Investors are now assessing the potential for further declines.

Investor Lawsuit Compounds Mounting Pressure

Adding to the company’s immediate challenges, a class action lawsuit has been filed on behalf of investors. The suit pertains to shareholders who purchased Hims & Hers stock between April 29, 2025, and June 23, 2025. Affected investors have until August 25 to step forward as lead plaintiffs.

The legal filing presents serious allegations. It claims the company engaged in fraudulent activity by promoting and selling what are described as “illegitimate, counterfeit versions of Wegovy® that endangered patient safety.” A more severe accusation suggests corporate leadership knowingly concealed material information from investors. The lawsuit contends that Hims & Hers failed to disclose the substantial risk that its controversial practices could lead directly to the dissolution of its key partnership with Novo Nordisk. The market reaction to these alleged misrepresentations was swift and severe, with the company’s share price declining by 10.2%.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Strategic Blow: Termination of Novo Nordisk Alliance

The foundation of this crisis was laid by a major strategic development. Danish pharmaceutical giant Novo Nordisk unexpectedly ended its collaboration with Hims & Hers. This partnership had been focused on the commercialization of GLP-1 weight-loss medications, representing a multi-billion dollar growth sector.

In a move that significantly alters the competitive dynamics of the telehealth weight-loss market, Novo Nordisk has subsequently entered into a new agreement with rival GoodRx. This new partnership will see GoodRx responsible for the distribution of FDA-approved drugs including Ozempic and Wegovy. For Hims & Hers, this represents both the loss of a strategically vital ally and the simultaneous strengthening of a direct competitor.

The critical question for the market is whether Hims & Hers can recover from this twin crisis or if the loss of investor confidence will prove too damaging to overcome.